The use of bone modifier therapy to reduce skeletal morbidity in patients with bone metastases should be considered.  Results of randomized trials of pamidronate and clodronate in patients with bony metastatic disease show decreased skeletal morbidity.  Zoledronate has been at least as effective as pamidronate.  The study suggest that the longer dosing interval of zoledronate every 12 weeks is a reasonable treatment option.

Source:  NCI  2019